Review



ivig product  (Kedrion Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Kedrion Inc ivig product
    Cumulative reporting of most frequent ADRs with <t>this</t> <t>Kedrion</t> 5% <t>IVIg</t> by frequency and seriousness (1 January 1997–31 May 20254).
    Ivig Product, supplied by Kedrion Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig+product/ivig/pmc13019492-98-20-18
    Average 86 stars, based on 1 article reviews
    ivig product - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database"

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    Journal: Current Therapeutic Research, Clinical and Experimental

    doi: 10.1016/j.curtheres.2026.100826

    Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).
    Figure Legend Snippet: Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Techniques Used:

    Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.
    Figure Legend Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Techniques Used:

    Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.
    Figure Legend Snippet: Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Techniques Used:

    Related Articles

    other:

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: This database includes the complete history of spontaneous, post-approval reports of ADRs with this product, and does not include GAMMAPLEX 5%, a different 5% IVIg product manufactured by Kedrion.

    Activity Assay:

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: This Kedrion 5% IVIg product, a solution of virus-inactivated, normal human immunoglobulin for intravenous use, was introduced into clinical practice in Italy in 1984 and has been marketed with the present formulation since 1992. .. This Kedrion 5% IVIg product is approved for replacement therapy in the treatment of a variety of PIDs and SIDs, and in clinical settings in which the immunomodulatory activity of IVIg therapy has been shown to be beneficial. ..

    Virus:

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: .. This Kedrion 5% IVIg product, a solution of virus-inactivated, normal human immunoglobulin for intravenous use, was introduced into clinical practice in Italy in 1984 and has been marketed with the present formulation since 1992. .. This Kedrion 5% IVIg product is approved for replacement therapy in the treatment of a variety of PIDs and SIDs, and in clinical settings in which the immunomodulatory activity of IVIg therapy has been shown to be beneficial.

    Formulation:

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: .. This Kedrion 5% IVIg product, a solution of virus-inactivated, normal human immunoglobulin for intravenous use, was introduced into clinical practice in Italy in 1984 and has been marketed with the present formulation since 1992. .. This Kedrion 5% IVIg product is approved for replacement therapy in the treatment of a variety of PIDs and SIDs, and in clinical settings in which the immunomodulatory activity of IVIg therapy has been shown to be beneficial.



    Similar Products

    ivig product  (Kedrion Inc)
    86
    Kedrion Inc ivig product
    Cumulative reporting of most frequent ADRs with <t>this</t> <t>Kedrion</t> 5% <t>IVIg</t> by frequency and seriousness (1 January 1997–31 May 20254).
    Ivig Product, supplied by Kedrion Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig+product/ivig/pmc13019492-98-20-18
    Average 86 stars, based on 1 article reviews
    ivig product - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ivig product  (Octapharma ag)
    90
    Octapharma ag ivig product
    Cumulative reporting of most frequent ADRs with <t>this</t> <t>Kedrion</t> 5% <t>IVIg</t> by frequency and seriousness (1 January 1997–31 May 20254).
    Ivig Product, supplied by Octapharma ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig+product/ivig+product/pm39919412-133-13-26
    Average 90 stars, based on 1 article reviews
    ivig product - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    ivig product gammaplex  (Kedrion Inc)
    90
    Kedrion Inc ivig product gammaplex
    Cumulative reporting of most frequent ADRs with <t>this</t> <t>Kedrion</t> 5% <t>IVIg</t> by frequency and seriousness (1 January 1997–31 May 20254).
    Ivig Product Gammaplex, supplied by Kedrion Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig+product/ivig+product+gammaplex/10__1016_slash_j__clim__2024__109949-60-11-10
    Average 90 stars, based on 1 article reviews
    ivig product gammaplex - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    ivig product octagam ® 10  (Octapharma ag)
    90
    Octapharma ag ivig product octagam ® 10
    Selected recently published pharmaceutical clinical trials on the treatment of dermatomyositis.
    Ivig Product Octagam ® 10, supplied by Octapharma ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig+product/ivig+octagam+10/pmc11034924-128-18-24
    Average 90 stars, based on 1 article reviews
    ivig product octagam ® 10 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    ivig and scig products  (Takeda)
    90
    Takeda ivig and scig products
    Selected recently published pharmaceutical clinical trials on the treatment of dermatomyositis.
    Ivig And Scig Products, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig+product/ivig+and+scig+products/pm38175703-39-12-0
    Average 90 stars, based on 1 article reviews
    ivig and scig products - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    ivig product nanogam  (Sanquin)
    90
    Sanquin ivig product nanogam
    Selected recently published pharmaceutical clinical trials on the treatment of dermatomyositis.
    Ivig Product Nanogam, supplied by Sanquin, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig+product/ivig+nanogam/pm34854474-159-1-4
    Average 90 stars, based on 1 article reviews
    ivig product nanogam - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

    Techniques:

    Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

    Techniques:

    Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

    Techniques:

    Selected recently published pharmaceutical clinical trials on the treatment of dermatomyositis.

    Journal: Current treatment options in rheumatology

    Article Title: Past, Present, and Future in Dermatomyositis Therapeutics

    doi: 10.1007/s40674-022-00193-6

    Figure Lengend Snippet: Selected recently published pharmaceutical clinical trials on the treatment of dermatomyositis.

    Article Snippet: While IVIg use had previously been used off-label for DM patients, the FDA recently approved the first and only IVIg product (Octagam ® 10%, Octapharma AG, Lachen, Switzerland) for use in adults with DM in July 2021.

    Techniques: Clinical Proteomics, Injection